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That some planets are uninhabited could very likely be 
because their nuclear scientists were more successful 
than ours.  







Cardiovascular disease is the largest cause of morbidity and mortality in the Western 
World. Disease progression often involves a loss of contracting cells, cardiomyocytes, 
which leads to cardiac failure and the need for heart transplantation with time. 
However the shortage of donor hearts is a large problem and a strong motivator for 
finding alternative solutions; this is the focus of regenerative heart medicine. For new 
treatment strategies to be effective we first need to better understand the potential and 
capacity of the heart and its cells. This thesis addresses two questions specifically: 1) 
Do cardiomyocytes renew in human hearts during healthy aging? 2) How does 
cardiac disease affect cardiomyocyte renewal? Studies in experimental animals and to 
a small extent in humans had previously not been able to resolve these questions, 
mainly because limitations in methods and ethical restrictions. We employed 
primarily two methodologies, 14C birth dating and mathematical modeling. 14C birth 
dating is a method developed within the Frisén group that exploits the changes in 
atmospheric 14C levels due to testing of nuclear weapons during the Cold War. The 
14C concentration in the genomic DNA of a cell reflects when the cell was born, and 
hence the level of renewal. The core part of the mathematical model is a first order 
partial differential equation (PDE). It describes cells according to their age and how 
the distribution of ages changes as the individual grows older. We found that human 
cardiomyocytes in healthy hearts indeed renew throughout life, with a declining 
turnover not exceeding 1% per year in adult life, and that the cell number is 
established already at birth. Endothelial and mesenchymal cardiac cells are more 
dynamic, both in terms of changes in cell number and baseline turnover (Paper II 
and IV). Preliminary results indicate that ischemic heart disease and dilated 
cardiomyopathy can increase the renewal rate to 2.7% per year; however it is likely 
that individual turnover estimates differ from this, which may reflect the differences 
in disease etiology and patient specific manifestation (Paper I). In order to reach 
these conclusions we developed a method to isolate cardiomyocyte nuclei, based on 
the molecular markers, PCM-1, cTroponin T, and cTroponin I (Paper III). This work 
shows that adult cardiomyocytes in healthy and diseased hearts have a measurable 
regenerative capacity, suggesting that it can be exploited for developing new 
therapeutic strategies to treat heart disease.  
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PERSONAL REFLECTIONS ON MY THESIS  
 
This thesis is part of my doctorate in Medicine, with a special focus on regenerative 
heart medicine. Regenerative heart medicine is the scientific investigation of 
myocardial regeneration, and aims to restore tissue damage and function caused by 
heart disease. It is a large field, reflecting the current and expected need for better 
treatments of this debilitating condition. Not much in biology is simple, but there is 
essentially just three ways in how to think about the perspective of completely curing 
a patient with heart failure; either you give the patient a new heart, or you give him 
new heart cells, or you help the heart to make its own new cells. The first one does 
not actually concern regenerative medicine; however, of the three options, it is the 
only one available today. When I started my PhD it was not known whether the 
muscle cells in the human heart (cardiomyocytes) naturally exchange in adult life, or 
we die with the same cells that we were born with. To a “knowledge-greedy” scientist 
this is of course a very intriguing question, but for the future of heart medicine the 
answer is of fundamental value. If the cardiomyocytes retain some capacity to renew 
it suggests that the third option, to help the heart help itself, is both rational and 
realistic. This is also the main question for my studies; does it occur in health and 
disease and to what extent? Although my studies deal with regeneration in the human 
heart, I have included some words about heart regeneration in other species as well as 
developmental heart biology, since they serve important roles as scientific inspiration 
and provide experimental models. Developmental biology can teach us about the 
mechanisms of cardiomyocyte proliferation when it occurs on an impressive level, 
such as in the embryonic and neonatal heart. Other species can provide similar 
insight, and experimental animals allow for hypotheses testing and manipulations that  




The heart – it beats as long as we live 
 
The human heart is built up of four chambers, the left and right ventricles and the left 
and right atria. This makes it a highly compartmentalized organ in which oxygen-rich 
and oxygen-poor blood is separated for efficient oxygenation of the body via the 
circulatory systems. The two circulation systems are the pulmonary circulation, 
connecting the lungs to the heart, and the systemic circulation that serves all tissues 
and organs. The blood supply to the cells of the heart itself is part of the systemic 
circulation through the coronary vessels. In addition to oxygenation, the blood 
circulation is also important for transportation of nutrients, water, and waste products. 
During one round of circulation, deoxygenated blood from the body enters the right 
atria through two large vessels called the superior and inferior vena cava (Figure 1). It 
then travels to the right ventricle, from where it is pumped out through the pulmonary 
arteries to the lungs. Here it takes up oxygen and releases carbon dioxide. The 
oxygenated blood then returns to the heart via the pulmonary veins, through the left 
atria, to reach the left ventricle. Subsequently the blood is pumped out through the 
aorta to the rest of the body. The pressure created in the arteries by the contraction of 
the left ventricle is called the systolic blood pressure; this is the higher blood pressure 
in the system and has an approximate value of 120 mmHg. After the contraction the 
ventricle begins to relax while the left chambers refill with blood from the pulmonary 
veins, during which the pressure is approximately 80 mmHg. During one minute at 
rest the heart makes 60-100 such contractions/relaxations. The cells responsible for 
the contractions are called cardiomyocytes. They comprise 20% of the cardiac cells, 
but in volume they take up more space than the other cells (endothelial cells, smooth 
muscle cells and cardiac fibroblasts). This is due to their large cytosols filled with 
contractile fibers (myofibrils), which are organized in sarcomeres, the basic unit of 
contraction. The sarcomeres make it possible for the myofibrils to slide across each 
other to change the length of the myocyte. The two main proteins of myofibrils are 
myosin (thick filament) that works as the motor in driving the contraction, and actin 
(thin filament) that binds to the boundaries (Z-lines) of the sarcomere and anchors the 
myofibrils. Cardiomyocytes are in majority polyploid cells, which mean that their 
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nuclei have more than two copies of each chromosome. Approximately 35% are 
diploid, 65% are tetraploid, and 5% are octaploid. These proportions are established 
during adolescence but can change during heart disease. Around 20% of the 
cardiomyocytes are also multinucleated, having more than one nucleus per cell. 
Endothelial and smooth muscle cells are diploid and make up the walls of the vessels 
in the myocardium. Cardiac fibroblasts are also diploid; they produce the extracellular 
matrix that gives structure and mechanical stability to the heart tissue. 
 
 
Figure 1: The human heart and the blood flow. Red and blue indicate oxygenated and de-oxygenated 
blood respectively.  
  
A brief insight into heart development  
 
The heart is the first organ to become functional during fetal development, and 
already at week 3 the primitive heart starts beating spontaneously. First the heart is 
just a tubular structure, called the primitive heart tube. This is a short-lived structure 
that is followed by morphogenesis at day 23, a process of stretching and looping that 
gives the heart its correct shape and its cells the correct spatial distribution. The main 
walls of the heart are formed during the fourth and fifth week, and by the ninth week 
the valves are completed. However, it is not until birth the heart fully separates the 
arterial and venous blood, and the pressure differences of the left and right side is 
established (closing of foramen ovale). Along with the heart’s structural development, 
the cells within it develop as well. The cardiac cells in the adult heart, 
atrial/ventricular cardiomyocytes, vascular smooth muscle cells, endothelial cells, and 
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cardiac fibroblasts, are generated from three sources of embryonic precursors: (1) the 
cardiogenic mesoderm, (2) the cardiac neural crest, and (3) the proepicardial organ. 
The cardiogenic mesoderm (mesoderm is one of the three embryonic tissues) is 
located to the cranial end of the embryo, anterior to the future brain, and can be 
divided into the first and second heart field (FHF and SHF respectively) (Kelly and 
Buckingham, 2002). The FHF and SHF precursor cells have acquired their name 
because of the timing of their contribution to the developing heart; the FHF provides 
cells already to the heart tube while the SHF adds cells during the looping stage. That 
this timing is crucial is evidenced by severe defects in the out-flow tract as a result of 
too early or too late differentiation of the SHF. The FHF primarily gives rise to the 
left ventricle and partly to the atria while the SHF develops into the right ventricle, 
ventricular septum, and the outflow tract. The outflow tract is a transient embryonic 
structure that connects the embryonic ventricles to the aortic sac, which gives rise to 
the ascending aorta and the pulmonary trunk (the base of the two pulmonary arteries). 
The cardiac neural crest migrates into the heart at later stages of development and is 
important for outflow-tract septation and proper differentiation of the early 
myocardium. The majority of the cardiac vessels are derived from the cardiac neural 
crest. The proepicardial organ develops into the mesenchyme portion (cardiac 
fibroblasts and smooth muscle) of the heart and the majority of the cells in the 
epicardium (outer layer of the ventricular wall) (Laugwitz et al., 2008).  
Since the advent of molecular biology in 1970, much knowledge has been 
attained about the different embryological cell types and the molecular signaling 
involved in cardiac development. This has provided a more detailed view of the 
developmental process, but also somewhat complimentary as distinct morphological 
structures not necessarily correspond to distinct cell types. For instance, to date there 
is no known set of molecular markers that define the first and the second heart field. 
However, the common progenitor has been shown to be marked by the transcription 
factors Mesp1/2 and Fgf8, which are expressed in the early cardiac mesoderm during 
the existence of the primitive streak (a region of cell movement that separates the 
mesoderm from the endoderm). A subsequent progenitor giving rise to all the cardiac 
cells has been shown to express the factors, Nkx2.5+/Isl1+/Flk-1+, and then by loss of 
either Nkx2.5 or Flk-1 muscle and vascular progenitors arise respectively (Bu et al., 
2009; Lam et al., 2009; Moretti et al., 2006). Cardiac fibroblasts may arise from the 
vascular progenitors through endothelial-to-mesenchymal transition. A potentially 
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distinct proepicardial progenitor, marked by Tbx18+ (T-box transcription factor) may 
also exist. This progenitor was shown to contribute to coronary smooth muscle, 
cardiac fibroblasts, and some atrial and ventricular cardiomyocytes (Cai et al., 2008). 
However, this finding has been questioned on the basis of the specificity of the 
genetic lineage tracing used (Christoffels et al., 2009). Recently, it was published that 
the earliest committed cardiomyocyte progenitor, referred to as the cardiomyoblast, 
has been identified (Jain et al., 2015). This cardiomyoblast was defined by the Hopx 
(homeobox gene) expression in cardiac progenitors from the SHF (Wnt-activated Isl+ 
progenitors) that are localized to the outflow-tract and start expressing Hopx after 
down-regulating Wnt. The hope is that furthering the understanding of the 
developmental mechanisms, and of the identity of progenitors committed to the 
myocyte lineage, will advance cardiac regenerative therapies. 
 
 
What goes wrong in heart disease? 
 
Heart disease is any disease that involves the heart and the cardiac blood vessels. It is 
a large class of diseases that can be separated into cardiomyopathies and non-
cardiomyopathies. The former is also referred to as primary heart disease and the 
latter secondary heart disease. According to the latest classification from the 
American Heart Association cardiomyopathy is defined as: “Cardiomyopathies are a 
heterogeneous group of diseases of the myocardium associated with mechanical 
and/or electrical dysfunction that usually (but not invariably) exhibit inappropriate 
ventricular hypertrophy or dilation and are due to a variety of causes that frequently 
are genetic. Cardiomyopathies either are confined to the heart or are part of 
generalized systemic disorders, often leading to cardiovascular death or progressive 
heart failure-related disability”. The non-cardiomyopathies include pathological 
myocardial processes and dysfunction that are direct consequences of other 
cardiovascular abnormalities such as valvular heart disease, systemic hypertension, 
congenital heart disease, and atherosclerotic coronary artery disease/ischemic heart 
disease (IHD) (Maron et al., 2006).  
Dilated cardiomyopathy (DCM) is characterized by ventricular chamber 
enlargement with maintained normal left ventricle wall thickness in the absence of 
coronary sclerosis, and systolic dysfunction. It is the third most common cause of 
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heart failure and the most common cause for heart transplantation. The cause can be 
genetic or non-genetic, including specific infectious agents and toxins; it has been 
reported that 20-35% of DCM are hereditary with association to more than 20 loci. 
The predominant mode of inheritance is autosomal dominant. Left ventricle chamber 
dilation can also occur as a secondary response to other cardiac conditions but should 
be distinguished from DCM, which is a primary heart disease. For instance, left 
ventricle myocardial hypertrophy can with time lead to chamber dilation, if the 
hypertrophy is so-called eccentric. This condition involves a thickening of the 
ventricle wall and is a consequence of cardiac volume or pressure overload, or to 
stimuli that are not yet completely understood (Borer, 2004). Hypertrophic 
cardiomyopathy (HCM) is, despite the similar name, not equal to left ventricle 
myocardial hypertrophy. HCM is an autosomal dominant genetic heart disease, which 
is the most common cause of sudden cardiac death (in the United States). HCM is 
assessed morphologically as an enlarged but non-dilated left ventricle in the absence 
of other systemic or cardiac disease related conditions such as systemic hypertension 
or aortic valve stenosis, which would instead lead to the diagnosis cardiac 
hypertrophy (non-cardiomyopathy that can occur with age for instance). HCM is 
caused by a variety of mutations that frequently involve contractile proteins (e.g. beta-
myosin heavy chain and myosin-binding protein C), mitochondrial genes, or proteins 
associated with metabolic pathways. Takotsubo cardiomyopathy, or more commonly 
known as broken heart syndrome, is an acquired cardiomyopathy that results from 
strong physiological stress (e.g. as in Paper I in which a mother lost her baby). Given 
the right medical treatment this condition has a good prognosis (Maron et al., 2006).      
Heart disease is also reflected on the cellular and extracellular level in various 
ways, collectively referred to as pathological myocardial remodeling. This process 
involves increased myocardial mass associated with hypotrophy of individual 
cardiomyocytes, alterations in gene expression, and changes in both the quantity and 
quality of the extracellular matrix. Depending on the nature of the pathological 
stimulus these alterations may take different forms. For instance systolic overload 
(e.g. from aortic stenosis) results in ventricular wall stress that promotes addition of 
sarcomeres in parallel, making the cardiomyocytes wider (concentric hypertrophy). If 
the wall stress is caused by an increase in ventricular diastolic volume instead (e.g. 
mitral regurgitation) the cardiomyocytes grow in length, as sarcomeres are added in 
series (eccentric hypertrophy). One prominent feature of ventricular remodeling is 
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pathological polyploidization of cardiomyocytes. This is a process in which the 
genome is multiplied, either through the creation of polyploid nuclei (e.g. tetraploid 
cells become octaploid) or by multinucleation. It is not known if pathological 
polyploidization is reversible but a study in patients with left ventricular assist devices 
suggests it is possible under such circumstances (Wohlschlaeger et al., 2010).  
Another feature is the re-expression of fetal genes (genes expressed during cardiac 
development) coding for atrial natriuretic peptide, brain natriuretic peptide, α-skeletal 
actin, fibroblast growth factor (FGF), and transforming growth factor β (TGF-β) 
(Colucci, 1997). The TGF-β is a large family of growth factors and individual 
members might exert different roles in disease; one of its growth hormone members 
(GDF11) is for instance implicated in reversal of age-related cardiac hypertrophy 
(Loffredo et al., 2013). FGF and TGF-β are important factors for the composition of 
the extracellular matrix. The extracellular matrix consists of structural proteins (e.g. 
collagen and fibronectin) that give structural support to the myocardium, and non-
structural proteins that have immune modulatory functions. During a myocardial 
infarction up to 1 billion cardiomyocytes might be lost, depending on the size of the 
infarction, and the vast majority of these will not be replaced (Laflamme and Murry, 
2011). Without the reparative actions of cardiac fibroblasts and fibrosis, the 
myocardium would be left with tissue ruptures (Dobaczewski et al., 2010; Savvatis et 
al., 2014). On the other hand the sealing of the ruptures may prevent the formation of 
new cardiomyocytes, which naturally would be the preferred new tissue together with 
new blood vessels. Studies in mice indicate that new cardiomyocytes can be produced 
after myocardial infarction; up to 4% of cardiomyocytes in the proximity to an infarct 
showed molecular evidence of proliferation (Bersell et al., 2009; Kimura et al., 2015; 
Malliaras et al., 2013; Senyo et al., 2013). However, whether new cardiomyocytes 
contribute during human heart disease is currently not known, but is the focus of 
Paper I.     
In recent years it has been increasingly appreciated that the immune system 
plays an important role in cardiac injury. It is involved both in the acute inflammatory 
response and the regenerative response. Much of its actions are believed to be a 
consequence of the primary function of the immune system – to maintain homeostasis 
following injury and infections, and that the cost of this is destructive inflammatory 
damage (Epelman et al., 2015). Resident cardiac immune cells are triggered by 
damage-associated molecular patterns, DAMPs, (or pathogen-associated molecular 
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patterns in myocarditis for instance) by a number of pattern recognition receptors 
(PPRs). The PPRs can for instance recognize the molecular patterns of dying or 
injured myocardial cells. The time course of the inflammatory response is remarkably 
consistent, irrespective of the cause of the injury, and entails a rapid influx of 
neutrophils followed by monocytes into the injured area. The involvement of the 
immune system in heart disease is best characterized in acute ischemic injury. 
Adaptive immune cells, like CD8+ T-cells, are known to act anti-inflammatory and 
reduce infarct size through their angiotensin receptor type II (AGTR2) and production 
of IL-10 (pro-fibrotic cytokine). Angiotensin II is part of the renin-angiotensin 
system, which has long been known to be a crucial pathological pathway in heart 
disease (Cohn and Tognoni, 2001; Dickstein et al., 2002). Angiotensin II is thought to 
primarily induce cardiomyocyte hypertrophy and increase vascular tone by signaling 
through AGTR1 and modulated by AGTR2 (Curato et al., 2010). The transition from 
acute inflammation to tissue fibrosis is mediated largely by macrophages through 
their production of anti-inflammatory and pro-fibrotic cytokines. The ensuing 
maturation of the fibrotic area leads to scar formation, which permanently limits the 
function of the heart. 
 
 
165 years of heart work 
 
From 1850 to the first quarter of the 20th century the common view among 
cardiologists was that cardiomyocytes in adult hearts are able to multiply (proliferate). 
How would it otherwise be possible to observe patients with larger than normal 
(hypertrophied) hearts (Carvalho and de Carvalho, 2010). The idea that this might not 
be true was suggested in 1925 (Karsner et al., 1925), based on the failure to detect 
mitotic figures in microscopic examinations of human cardiomyocytes collected from 
hypertrophied hearts. This led to the long-held view of the heart being a post-mitotic 
organ in which cardiomyocytes can only grow in size but not in numbers. It was not 
until the late 1990s that the first indications of cardiomyocyte proliferation started to 
appear (Beltrami et al., 2001; Kajstura et al., 1998). Kajstura et al. reported in 1998 
cardiomyocyte mitotic indexes in the range of 10-5 and 10-4 in healthy and diseased 
hearts respectively. The extrapolated turnover suggested that all cardiomyocytes are 
exchanged within a few years. This made cardiac researchers open up for the 
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possibility that cardiomyocytes might be able to divide after all. However, data on 
cardiomyocyte DNA synthesis in other mammals such as mouse and rat, which often 
are used as models for human hearts, was highly variable and raised questions about 
the actual magnitude of cardiomyocyte renewal (Soonpaa and Field, 1998). It is likely 
that at least part of the variability can be explained by the different methods used to 
detect DNA synthesis and identify cardiomyocyte nuclei. The importance of accurate 
identification of cardiomyocytes and their ploidy prompted us to publish a method 
paper on this topic (Paper III).  
This was around the time when the field of stem cells was growing fast and the 
beginning of the present stage, from which regenerative medicine has grown. The first 
stem cells to be identified were those of the blood system (hematopoietic stem cells), 
residing in the bone-marrow and expressing the factors, c-kit and Sca-1 (Lkuto et al., 
1991). It had been suggested that these cells not only contributed to the blood lineage 
but also to other tissues (Krause et al., 2001), which led to the claim that this was true 
for the heart as well (Orlic et al., 2001). The idea that the heart could be renewed by 
stem cells outside the heart, referred to as extracardiac stem cells, was also reinforced 
by studies in humans. These were based on gender-mismatched transplantations in 
which female hearts were found to harbor Y-chromosome-positive cardiomyocytes 
(Deb et al., 2003; Laflamme et al., 2002; Muller et al., 2002). However, it was soon 
after shown that the cells from the bone marrow were not stem/progenitor cells, nor 
did they differentiate/transdifferentiate, but were instead fusing with the 
cardiomyocytes in the donor hearts or adopted a mature hematopoietic fate (Alvarez-
Dolado et al., 2003; Balsam et al., 2004; Murry et al., 2004; Nygren et al., 2004). 
Nevertheless, it was suggested that the heart does contain proliferating immature cells 
(c-kit+/Sca-1+/lin-), and these cells were coined resident cardiac stem/progenitor cells 
(CPCs) (Beltrami et al., 2003).   In trying to characterize the CPCs a plethora of 
marker profiles and properties that would identify them were generated. When using 
the term CPCs today it usually refers to one of the following populations: side 
population (Martin et al., 2004), c-kit+ (Beltrami et al., 2003; Dawn et al., 2005), 
Sca1+ (Oh et al., 2003; Tateishi et al., 2007; Uchida et al., 2013), SSEA1+ (Ott et al., 
2007), and cardiosphere-derived CPCs (Messina et al., 2004; Smith et al., 2007). 
Among these, the c-kit+ population has got the most attention by far, which is linked 
to Anversa and his colleagues being strong proponents of their potential (Leri et al., 
2014). It should be noted that the CPC populations are not mutually exclusive; for 
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instance cells can be both c-kit+ and Sca1+. It has been shown that CPCs populate the 
heart at a low frequency with an estimate of 1 per 40,000 cardiac cells in mouse 
(Hosoda et al., 2009). According to the classical definition of a stem cell the CPCs 
should be able to give rise to all the cell types of the adult heart, including 
cardiomyocytes. However, since it was recognized that it is very difficult to know the 
fate and functional role of CPCs, only based on immunohistological identification, 
there was a need to address this issue in another way. Today this is commonly 
performed by advanced genetic fate mapping strategies in transgenic mice (most 
often), in which recombination can be controlled (see section Techniques for studying 
cardiomyocyte renewal). However, early efforts to trace the fate of c-kit+ cells were 
performed using non-inducible tracing strategies. They were instructive in studying c-
kit+ expression during development and after injury, but could not address if the c-
kit+ cells differentiated into cardiomyocytes (Ferreira-Martins et al., 2012; Fransioli 
et al., 2008; Tallini et al., 2009). The first important contribution to study 
cardiomyocyte renewal using a conditional genetic fate-mapping approach was made 
by Prof. Richard Lee and his group at Harvard (Hsieh et al., 2007). In an elegant 
approach using transgenic mice they traced cardiomyocytes instead of CPCs (which 
has proven to be very difficult). They labeled cardiomyocytes with GFP (green 
fluorescent protein) under the control of Myh6 (α-myosin heavy chain) promotor, 
recorded the labeling frequency, waited one year to reflect normal aging or performed 
an ischemic injury, and then analyzed the recombination frequency again. With this 
strategy they detected a dilution of GFP labeled cardiomyocytes bordering the 
infarction, indicating that cardiomyocytes were renewed by unlabeled (GFP negative) 
progenitors. It was also shown that these progenitors could be stimulated by 
transplantation of bone-marrow derived c-kit+ cells (Loffredo et al., 2011). However, 
during normal aging no cardiomyocytes were renewed (Hsieh et al., 2007). This was 
in stark contrast to the magnitude of renewal argued by Anversa and his colleagues, 
who had published turnover rates of 50-80% per year in mice and 7-40% per year in 
humans (Hosoda et al., 2009; Kajstura et al., 2010a; Kajstura et al., 2010b). It was 
however consistent with our estimates of less than 1% per year in adulthood (Paper II 
and IV).   
Heart regeneration is also studied in lower vertebrates, and in zebrafish 
cardiomyocytes regenerate primarily by means of epicardial cardiomyocytes (gata4+) 
that dedifferentiate, proliferate, and relocate to sites of injury  (Jopling et al., 2010; 
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Kikuchi et al., 2010; Poss et al., 2002). In fact the epicardium (and sub-epicardial 
layer) might be a region with higher regenerative potential, as also suggested in 
(Smart et al., 2011), by harboring cells able to re-express Wt1 (Wilm’s tumor 1) upon 
thymosin β4 priming. This inspired us to investigate regional differences of 
cardiomyocyte turnover in humans (Paper II). In a recent study, applying advanced 
multi-isotope imaging mass spectrometry (MIMS) technology, Richard Lee’s group 
showed that also cardiomyocytes in the mouse heart regenerate mainly through self-
duplication (Senyo et al., 2013). The apparent discrepancy with their previous study 
probably reflects the difficulties in studying biological processes without interfering 
with them (see section Techniques to study cardiomyocyte renewal). Consequently, 
the researchers in the field could not agree on a unified view on the regenerative 
capacity of the adult mammalian heart, or whether new cardiomyocytes come from 
self-duplication or progenitor cells. Anversa and colleagues are still strong proponents 
of the potential of the c-kit+ cells (Ellison et al., 2013), while many other 
investigators in the field are less convinced (van Berlo and Molkentin, 2014). 
Although there is evidence for c-kit+ cells contributing to new cardiomyocytes after 
injury in the neonate, they fail to do so even after favorable inductive conditions in 
the adult heart (Jesty et al., 2012). The c-kit+ cells have now also been investigated by 
means of conditional fate-mapping (during development, aging, and after injury in 
adulthood) and it was then shown that c-kit+ cells do not contribute meaningfully to 
cardiomyocyte regeneration (van Berlo et al., 2014). In general new transgenic tools 
have made it easier to trace the progeny of potential stem cells. Recently it was 
shown, by an inducible Cre-labeling approach, that Sca-1+ CPCs are able to generate 
cardiomyocytes during normal aging and after injury (Uchida et al., 2013). In this 
study individual Sca-1+ cells were however biased towards a specific cell fate, which 
could be concluded from using the so called R26R-Confetti reporter mouse.  
Working along the lines of cardiomyocyte self-duplication the neonatal period 
and young individuals have been studied to get insight into which factors are in play 
when the cardiomyocytes have, or might have, a robust regenerative capacity (Walsh 
et al., 2010). In mice it was determined that a proliferative window exists during the 
first 7 days in the neonatal mouse, after which cardiomyocytes lose their ability to 
divide (Porrello et al., 2011). Both in humans and mice it was suggested that the 
cardiomyocyte number increases postnatally (Mollova et al., 2013; Naqvi et al., 
2014), but earlier studies did not find this (Mayhew et al., 1997), and we have 
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disputed it based on both design-based stereology and radiocarbon measurements 
(Paper II and (Alkass et al., submitted)).  
Perhaps because of the controversies regarding the mode and magnitude of 
cardiomyocyte renewal, efforts in recent time have a strong focus on mechanistic 
evidence. For instance, the oxygen level in the heart is emerging as an important 
factor in negatively regulating proliferation. The metabolic transition from anaerobic 
glycolysis to oxidative phosphorylation at birth has been shown to induce cell-cycle 
arrest in the majority of cardiomyocytes via the DNA-damage response (Puente et al., 
2014). Building on this, the same group showed earlier this year that a small 
subpopulation, constituting 0.05% of the total cardiomyocytes, remain proliferative 
and are characterized by being hypoxic (Kimura et al., 2015). Since accumulating 
evidence indicates that the main mode of renewal is self-duplication efforts have been 
made in trying to control the cardiomyocyte cell cycle in vivo. For instance, it has 
been shown that cardiomyocytes in mouse hearts can be induced to proliferate by 
supplying the growth factor neuregulin1, a ligand to the cardiomyocyte tyrosine 
kinase receptor ErbB4 (in this study undifferentiated progenitors did not contribute to 
the proliferative response) (Bersell et al., 2009). The transcriptional co-factor Yap, 
which acts in the hippo signaling pathway, has been found to not only regulate 
proliferation in embryonic cardiomyocytes but also activate the proliferative program 
in adult cardiomyocytes upon forced expression (Xin et al., 2013). Genetic deletion of 
Meis1 in mouse cardiomyocytes is sufficient for reactivating the proliferative 
program, without any deleterious effects in the adult heart (Mahmoud et al., 2013). 
Meis1 is a homeodomain transcription factor required for normal heart development, 
and a negative regulator of cardiomyocyte proliferation. The Alström protein Alms1 
has been shown to act in the same direction, as evidenced by a mutation in the 
ALMS1 gene leading to increased cardiomyocyte proliferation in affected infants 
(Shenje et al., 2014). Recently two microRNAs (miRNA), hsa-miR-590 and hsa-miR-
199a, were found to promote cell cycle re-entry of cardiomyocytes and restoration of 
cardiac function after myocardial infarction in adult mice (Eulalio et al., 2012). 
miRNAs are small non-coding RNA molecules that have emerged as important 
factors in RNA silencing and post-transcriptional regulation of gene expression. The 
miRNAs can play diverse regulatory roles and a member of the miR-15 family has for 
instance been shown to repress cardiac regenerative capacity in the neonate (Porrello 
et al., 2013). By learning from studying different life stages from the embryo to the 
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adult, considering different species, and employing different techniques, the 
knowledge about cardiac regeneration seems to converge to one picture; the annual 
turnover of cardiomyocytes in adult mammals is most likely below 2% and the main 
source for the regeneration is the cardiomyocytes themselves (van Berlo and 
Molkentin, 2014).  
 
 
A few words on transplantation strategies  
 
This thesis has focused on the heart’s potential to regenerate itself, also called 
endogenous regeneration. In regenerative heart medicine there are two main 
strategies, one is based on promoting and enhancing the endogenous regenerative 
potential therapeutically (Bergmann and Jovinge, 2014; Bersell et al., 2009; Kuhn et 
al., 2007; Lorts et al., 2009), and the other is to transplant exogenous cells in some 
context to the weakened heart. The main disadvantage with the latter is that life-long 
immunosuppression is often needed following the transplantation, which makes the 
former an attractive alternative. With the transplantation strategy, many different 
types of cells have already been tried in pre-clinical and clinical settings, including 
skeletal myoblasts, bone marrow-derived hematopoietic cells, mesenchymal stem 
cells, adipose-derived cells, endothelial progenitor cells, and cardiac-derived cells 
(e.g. c-kit+ cells and cardiospheres), for a review see (Behfar et al., 2014; Gerbin and 
Murry, 2015). If the goal is to provide the diseased heart with new cardiomyocytes 
one may wonder why cardiomyocytes is not on this list. In fact transplantation of 
cardiomyocytes has been tried, but was not successful at the experimental stage in rats 
(Reinecke et al., 1999). Although cardiomyocytes from fetal and neonatal rat hearts 
survived in the recipient hearts the adult cardiomyocytes did not (Reinecke et al., 
1999). 
There are many requirements that transplanted cells must fulfill in order to be 
beneficial to the heart. In addition to surviving, they also need to integrate, possibly 
differentiate, and electrically couple and beat synchronously with the host 
myocardium. The latter is one of the most challenging issues to resolve; too mature 
cells, like terminally differentiated cardiomyocytes, are not plastic enough to adjust to 
the new environment and therefore die, and too immature cells, including stem or 
progenitor cells, need complex guiding cues to be of any benefit or not be harmful 
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(e.g. proarrhythmic). Attempts on guiding include in-vitro differentiation, addition of 
small molecules (e.g. cytokines, peptides) to the transplantation cocktail, addition of 
other cells (that secrete paracrine factors), and placing the cells in engineered sheets 
that provide structural support (Zimmermann et al., 2006).  
Most transplantation strategies must thus involve both finding a good cell 
source and finding out how to properly guide the cells. Human embryonic-stem-cell-
derived cardiomyocytes (hESC-CMs) is one example, which has shown promising 
results in a study using an infarction model in monkeys (Chong et al., 2014). These 
cardiomyocytes integrated and survived in the infarcted myocardium (up to 3 
months), and electrically coupled to the host cardiomyocytes. Nonfatal arrhythmias 
were observed however, which needs to be managed for safe translation to the clinic. 
Another example is a preclinical study on pigs, in which induced pluripotent stem 
cells (iPSC) were differentiated into a desirable maturation stage of cardiomyocytes 
(Kawamura et al., 2012) before transplantation. iPSC are engineered cells obtained by 
reprogramming somatic cells using exogenous transcription factor cocktails 
(Takahashi and Yamanaka, 2006). The two main advantages with iPSC are that they 
allow for autologous transplantation, circumventing immunosuppression, and can be 
produced in sufficient numbers from the patient’s own dermal fibroblasts for instance. 
In fact the first clinical trial using iPSC to treat a degenerative eye disease was 
recently launched in Japan (Li et al., 2014). However, iPSC are still mainly used as 
scientific tools in experimental animal research and disease modeling in vitro. The 
field of reprogramming cells has grown rapidly after the introduction of iPSC, and has 
for instance been used to reprogram cardiac fibroblasts directly (not via iPSC) (Ieda et 
al., 2010). Clinical heart trials in humans using CPCs have proven to be safe in 
general but only moderately improve clinical parameters such as LV ejection fraction 
(Bolli et al., 2011; Makkar et al., 2012; Makkar et al., 2014). The effect is thought to 
be mediated by paracrine factors, which the transplanted cells secrete (or promote the 
host tissue to secrete). However, they have not been successful in providing new 





Techniques for studying cardiomyocyte renewal 
 
Cell proliferation and apoptosis (cell death) is often studied on tissue sections by 
visualization of molecular markers present in various stages of the cell cycle. The 
most common markers for proliferation are the protein Ki-67, and the phosphorylated 
form of histone-H3 (PHH3). Ki-67 is expressed during all active phases of the cell 
cycle (G1, S, M, G2), and histone-H3 is phosphorylated during the M-phase 
(prophase, metaphase, anaphase, telophase). The S-phase and the M-phase are the 
stages in the cell cycle where DNA is synthesized and the nucleus divides 
respectively, which are commonly followed by cytokinesis/cellular division. 
Polyploidization and multinucleation are exceptions to this and are examples of 
abortive cytokinesis. Apoptosis is studied with the TUNEL (Terminal 
deoxynucleotidyl transferase dUTP nick end labeling) technique, which detects 
fragmentation of DNA (and also to some extent other forms of cell death (Kraupp et 
al., 1995)). Detecting and counting cells positive for these proliferation and apoptosis 
markers gives a snapshot of the process and thereby some information on which cells 
are being renewed and to what extent at the time of analysis. If then the duration of 
the proliferation/apoptosis phase is considered it is possible to calculate how many 
cells are added/die per day, per year, and so on. However, there is no consensus on 
the length of the apoptotic phase and estimates range from a few hours to days, which 
makes the extrapolated value unreliable. Also the extrapolation from fractions per day 
to fractions per year implicitly assumes a constant death rate, which might not be the 
case. Usually the reason for performing such analyses is to gain more knowledge 
about the regenerative capacity of a tissue and its cells. With this aim there are 
additional limitations using cell cycle markers; one is that the cells might be renewed 
by a progenitor/stem-cell source and then it is difficult to assess the fate of the 
proliferating cells, or the proliferating cells may constitute a subpopulation among 
otherwise quiescent cells, which would then overestimate the turnover. These 
limitations probably reflect the large variation seen in the reports on mammalian 
cardiomyocyte turnover. Some studies failed to detect any renewal (Bersell et al., 
2009) while others found that cardiomyocytes renew several times during a lifetime 
(Kajstura et al., 2010a; Kajstura et al., 1998). 
Using experimental animals it is possible to overcome some of these 
limitations. One frequently used method is to use BrdU (Bromodeoxiuridine) and 
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label proliferating cells continuously over some time, thereby avoiding extensive 
extrapolation of the data. BrdU is a modified nucleic acid base with bromine attached 
to it, which makes it possible to distinguish the cells that recently synthesized DNA. 
However, the compound is toxic during prolonged administration, so it is not possible 
to track proliferation over extended time periods. In fact both BrdU and its analogue 
IdU are sometimes used as radiosensitizers in treatments of cancer patients (Kajstura 
et al., 2010b). The MIMS technology can overcome this limitation by using non-
radioactive tracers such as 15N-thymidine (Lechene et al., 2006). 15N-thymedine, like 
BrdU, is incorporated during DNA synthesis when administered to the subject 
(experimental animal or human). The labeled cells are subsequently visualized in an 
atomic mass image created by ionizing a fraction of the tissue sample. The image is 
created by the combined use of ion microscopy and ion mass spectrometry, which 
allows both qualitative and quantitative information to be recorded. The MIMS 
technology was recently used to visualize cardiomyocyte division (Senyo et al., 
2013).  
Another method for tracing cell fates in transgenic experimental animals is the 
Cre-loxP technique. In this technique the genetic construct for the enzyme, Cre 
recombinase (Cre), is inserted under the control of a cell specific promotor (controls 
gene expression) and the loxP recognition sites are placed flanking a stop-codon 
upstream of a gene coding for a reporter protein (e.g. EGFP, enhanced green 
fluorescent protein, originally from the jellyfish Aequorea victoria). Upon activation 
of the cell specific promotor Cre is expressed, which leads to the excision of the stop 
codon via the loxP sites (the recombination event), thereby allowing also expression 
of the reporter. This requires breeding of two transgenic mice, one containing Cre and 
the other the reporter protein (e.g. the Rosa26 reporter mouse). The advantage of the 
Cre-loxP technique is that both the cells of interest and its progeny will be 
permanently labeled through the general expression of the ROSA26 locus. There is 
also a tamoxifen-inducible form of Cre that can be used to control the timing of the 
recombination event and hence when the cells are labeled. However, limitations to the 
Cre-loxP technique include possibly low recombination efficiency (fraction of 
recombined/labeled cells), which can make it difficult to draw conclusions on the 
whole cell population. In addition there is potential toxicity associated with tamoxifen 
(Bersell et al., 2013). This technique has for instance been used to trace 
cardiomyocytes (Hsieh et al., 2007). In light of the above discussion, and the limited 
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alternatives for studying cell renewal in humans, our method of 14C birth dating has 
become a very powerful tool in investigating cardiomyocyte turnover. The main 
advantage is that turnover can be studied retrospectively, without interfering with 
biological processes, and even very small annual turnover rates can be detected due to 
the cumulative recording of 14C in the genomic DNA over time.     
 
 
14C birth dating 
 
14C is the heaviest of the three carbon isotopes (12C, 13C, 14C) and exists naturally in 
the atmosphere due to cosmic ray interactions with nitrogen. Normal atmospheric 
levels of 14C are very low but testing of nuclear weapons during The Cold War 
resulted in a dramatic increase, reaching its maximum in 1964 (Figure 2). Since then 
the levels are decreasing, which is attributed to diffusion and interaction mainly with 
the oceans. The radioactive decay contributes only minimally since the half-life of 14C 
is 5730 years (Levin and Kromer, 2004). 14C in the atmosphere reacts with oxygen to 
produce carbon dioxide, which enters the biotope through photosynthesis, and is 
subsequently taken up by humans through the intake of vegetables and animals that 
live off plants. The transfer of 14C from carbon dioxide to living material is fast as 
documented by carbon dating of tree rings (Figure 2), and specimens from subjects 
that died from sudden infant death syndrome (Spalding et al., 2005).  
 
 
Figure 2: (A) Atmospheric 14C levels were low and constant for thousands of years until 1955 when it 
spiked due to testing of nuclear weapons. (B-C) Validation of the transfer of 14C from the atmosphere 
to the biotope, here exemplified by tree rings. (C) Magnification of the spike in (A).     
 
This is because all living organisms frequently exchange carbon via metabolism. 
However, on a molecular level the exchange can vary greatly depending on the 
specific molecule. DNA is the most stable biological molecule and exchange carbon 
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essentially only during cell division, which means that changes in the carbon 
composition reflects the cell’s division history. We have taken advantage of this and 
developed a method to retrospectively date cells in the human body, including the 
heart (Paper I, II and IV). We refer to this method as the 14C birth dating technique. 
Nucleotide exchange in post-mitotic cells is minimal and below the detection limit of 
the technique (Bergmann et al., 2012; Bhardwaj et al., 2006; Huttner et al., 2014). The 
sensitivity for detecting cell turnover depends on: 1) when the individual was born in 
relation to when the cells were born; the larger the 14C difference the larger the 
sensitivity, 2) the proportion of cells in the population that turns over; under optimal 
conditions we can detect a subpopulation making up 1% of the total population 
(Spalding et al., 2005) and 3) the number of individuals analyzed. However, it will 
never be possible to reach single cell resolution since the atmospheric 14C 
concentrations are too low for every cell’s genome to contain even one 14C atom.  To 
achieve the highest sensitivity we have developed a sorting strategy to isolate 
cardiomyocyte nuclei from other cardiac cell nuclei. This entails antibody labeling of 
the cardiomyocyte nuclear specific antigens PCM1 (pericentriolar material-1) and 
cardiac troponin-I and T, and fluorescence-activated cell sorting (FACS) of these 
labeled nuclei (Figure 3).  
 
 
Figure 3: FACS analysis and sorting of isolated cardiac nuclei based on PCM-1 labeling to identify 
cardiomyocyte nuclei. (A) Nuclei labeled with an isotype control to the anti-PCM-1antibody (rabbit 
IgG), to control for unspecific labeling. (B) Nuclei labeled with anti-PCM-1 clearly separates 
cardiomyocyte (PCM-1+) from non-cardiomyocyte nuclei on forward scatter (FSC). (C) PCM-1 and 
cTroponin I co-labeling shows that both markers label the same population (cardiomyocyte nuclei). 
Lines indicate FACS gates for the sorting of cardiomyocyte and non-cardiomyocyte nuclei.     
 
High-purity sorted nuclei are subsequently processed for DNA extraction, and the 14C 
concentration in the DNA is measured with Accelerator Mass Spectrometry (AMS). 
The AMS measurement includes a preprocessing step in which the sample is 
combusted to CO2 and then graphitized. During this step the mass of the DNA sample 
A B C 
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is also determined, which serves as an additional control to make certain that no 
contamination has entered the sample (Salehpour et al., 2008).  
The 14C concentration of the DNA is reported as Δ14C, which is a relative unit 
normalized to an international standard and corrected for isotope fractionation (lighter 
isotopes are more reactive in chemical reactions) and decay. The first step in 
interpreting a 14C value is to visualize it by plotting the atmospheric bomb curve, 
mark the birth date of the individual with a vertical line, and the measured 14C value 
with a circle on the line. This gives an indication of the level of turnover in the 
population; for instance circles that display large deviations from the bomb curve 
indicate high turnover while circles located on the curve indicate no turnover. 
However, to be able to gain a more detailed description of the renewal, such as yearly 
turnover rates, a mathematical model is needed. The model presented here (see 
section Mathematical modeling of cell turnover, and Paper I, II, and IV) provides this 
by predicting the measured 14C concentration in the population through formulation of 
birth, death, and polyploidization of cells.  
 
 
Mathematical modeling of cell turnover 
 
Although there are several quite diverse strategies when analyzing cell turnover, I will 
in this section limit the description to our core model, the so-called age-structured 
partial differential equation (PDE).  
The measured 14C value of a cell population is an average of the 14C 
concentrations of the individual cells making up the population. This implies that the 
cells should be described by a cell specific feature, reasonably their age. This is 
because if we know how old a cell is we also know when it was born, and 
consequently what 14C it incorporated. The cell age is denoted a. As mentioned above 
(section 14C birth dating) the possible 14C values that can occur in an individual 
depend on when the individual lived; for the same reason as we keep track of the cell 
age we should also keep track of the individual’s age, denoted t. Here we define the 
time of birth of the individual to be t = 0 (i.e. not the actual calendar birth year). 
Furthermore, we want to describe the cell density, n, in order to use a conservation 
law for the derivation of the PDE. The cell density is the number of cells within an 
age class (a, a + Δa) at time t, and is therefore described as n (t, a). A conservation 
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law is one of the fundamental laws of nature, stating that that some quantity in a 
closed system is conserved. In this case we choose to conserve the density of cells, i.e. 
the density is the same within all age classes. Consequently, we are only considering 
aging of cells; however, we will shortly also include cell death and birth. The rate of 
change of the cell density can be thought of as a flux, J, a process commonly used in 
physics that refers to a flow rate (per unit area) of a quantity, for instance mass or 
charge. Here it relates to cells that flow or get transported through different age 
classes as the individual growths older, and the unit is cells per year instead. Hence, 
the rate of entry of cells, aged a, into an age class, minus the rate of their departure at 




Δ𝑎𝑎 = 𝐽𝐽(𝑡𝑡,𝑎𝑎) − 𝐽𝐽(𝑡𝑡,𝑎𝑎 + Δ𝑎𝑎) 
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.                                                  (1) 
 
For an in depth treatment of population dynamics see for instance Perthame’s 
Transport Equations in Biology (Perthame, 2006). To express the flux in a meaningful 
way we note that all cells become older in the same way. Hence we can assume that 
the flux is proportional to the cell density, i.e.  
 
𝐽𝐽(𝑡𝑡, 𝑎𝑎) = 𝑣𝑣 ∙ 𝜕𝜕(𝑡𝑡, 𝑎𝑎),                                                    (2) 
 
where v is the rate of aging. Furthermore, aging corresponds one-to-one to the passage 
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= 0.                                                  (4) 
 
We have not yet included that cells may die and that new cells can be born. Hence, we 






= −𝜇𝜇(𝑡𝑡,𝑎𝑎)𝜕𝜕(𝑡𝑡,𝑎𝑎)                                      (5) 
 
Equation (5) states that the change in cell density with time and with cell age equals 
the fraction of cells lost by cell death. This is a linear partial differential equation that 
was first developed by McKendrick to describe infectious spread (McKendrick, 
1925). In addition to our application of it (Bergmann et al., 2009; Bergmann et al., 
2015; Bernard et al., 2010; Yeung et al., 2014), there are applications in demography 
and ecology, which also take advantage of its age-structure (Mohr et al., 2014). To 
include birth of new cells we add another equation that serves as a boundary 
condition, i.e. on the boundary a = 0  
 
𝜕𝜕(𝑡𝑡, 0) = 𝛽𝛽(𝑡𝑡).                                                          (6)     
 
To have cell birth on the boundary is natural since birth only concerns cells with age 
zero (unit of β: cells/year). For the initial distribution (initial condition) of cell ages 
we have the generalized Dirac delta function, which is non-zero only when a = 0 
 
𝜕𝜕(0,𝑎𝑎) = 𝑁𝑁0𝛿𝛿(𝑎𝑎).                                                      (7) 
 
This assumes that all cells are newborn, i.e. have age zero, when the individual is 
born. The solution to (5), together with the side conditions, (6) and (7), is found by 
the method of characteristics (Figure 4 and Paper II and IV). For a ≤ t it has the closed 
form solution  
 





Figure 4: Method of characteristics for solving the PDE. The characteristics are straight lines with 
slope 1 and the solution is the sum of the solutions on all the characteristics (blue, red, and green). In 
the standard version of the PDE, concerning the red and green characteristics, the subject is older or 
have the same age as the cells (t ≥ a). In the two-phase PDE (see Paper II) blue characteristics are also 
used. Cells grow older along the characteristics and the blue dots represent the probability of cells 
surviving from age a-t to age a. The initial distribution of cell ages (initial condition) is defined where 
the blue and red characteristics cross the a-axis. Cell birth is defined where the green characteristics 
cross the t-axis.      
 
Hence the solution is a cell age distribution at time t during the life of the individual. 
However, we are most interested in the solution at the time point when the individual 
died, or the heart was collected (t = T). This distribution specifies when the cells, still 
present at heart collection, incorporated carbon. The average 14C concentration in the 
population, Cpopulation, is found by integrating over the solution, using the part of the 
bomb curve relevant to the individual, C(a). Then we have 
  
𝐶𝐶𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑎𝑎𝑡𝑡𝑝𝑝𝑝𝑝𝑝𝑝 = ∫ 𝜕𝜕(𝑡𝑡,𝑎𝑎)𝐶𝐶(𝑎𝑎)d𝑎𝑎𝑇𝑇0 𝑁𝑁(𝑇𝑇) ,                                                 (9) 
 
where N(T) is the total cell number. N(T) is found by integrating (8) over the cell ages 
0 to T. The interpretation of (9) is that the differently aged cells are weighted with 
different 14C concentrations, according to the bomb curve, and then normalized to the 
total cell number. It should be pointed out that the above Cpopulation refers to the non-
cardiomyocytes in the heart (diploid cells). Since cardiomyocytes polyploidize during 
adolescence, part of the carbon incorporation is not associated with cell turnover; we 
22  
have taken this into account by adjusting the 14C weights (Cadjusted (a), see Paper IV). 
Depending on the birth and death rates of cells, different age distributions are 
obtained and, consequently, different values on the estimated 14C in the population. 
The modeling of cell turnover consists of finding these rates so that the measured 14C 
can be reproduced.         
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SUMMARY AND DISCUSSION 
 
We have addressed two fundamental questions in regenerative heart medicine: do 
human cardiomyocytes turn over in homeostasis (Paper II and IV), and do 
cardiomyocytes contribute to the regenerative response in human heart disease (Paper 
I). To support the reached conclusions we published a method paper on how to 
accurately identify cardiomyocyte nuclei and their ploidy (Paper III).  
In Paper IV we investigated cardiomyocyte turnover in the left ventricle of the 
healthy adult human heart. By 14C birth dating and mathematical modeling we found 
that cardiomyocytes turn over with an annual rate of 1% in young adults, declining to 
0.45% in advanced age. This was the first study to show that cardiomyocytes in the 
human heart turn over in a life-long process and that the rate is much lower than was 
previously suggested (Anversa and Nadal-Ginard, 2002; Kajstura et al., 1998). Since 
the turnover we reported was low, it was claimed that our use of cTroponin I only 
targeted old and senescent cardiomyocytes and therefore did not represent the whole 
cardiomyocyte population (Kajstura et al., 2010b). However, it is very unlikely that 
this is true, because the cardiac nuclei that were negative for these markers did not 
express the cardiomyocyte genes Nkx2.5, Gata-4, or MHC. This shows that we did 
not exclude any cardiomyocytes, at least not any defined by the established 
characteristics. The cTroponin I negative cells instead expressed von Willebrand 
factor, vimentin, ACTA2 and CD45, consistent with being fibroblasts, endothelial 
cells, and smooth muscle cells. This makes us convinced that the magnitude of 
cardiomyocyte turnover we have reported reflects the true turnover well.  
In Paper III we showed that the nuclear cardiomyocyte markers cTroponin I/T 
and PCM-1 are accurate and sufficient markers to isolate the full complement of 
cardiomyocyte nuclei. We performed this study to strengthen the evidence for the 
validity of our markers. We also wanted to investigate and confirm the mainly 
polyploid status of cardiomyocytes, which Anversa et al. had been arguing against to 
support their high cardiomyocyte turnover level. All investigations of cardiomyocyte 
renewal need to accurately account for polyploidization since the DNA synthesis it 
entails can easily be mistaken for proliferation if care is not taken. Therefore we 
assessed ploidy both on isolated cardiomyocyte nuclei and in tissue sections. From 
this analysis it was clear that the majority of cardiomyocytes in healthy hearts are 
tetraploid. Anversa et al. used thin sections in their analysis and it is likely that many 
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of the large polyploid nuclei, which we found to have a diameter of >4um, were cut 
and therefore not counted. We also reanalyzed data from a previous study (Kajstura et 
al., 2010b) that used the presence of high levels of iododeoxyuridine (IdU) in 
cardiomyocytes as evidence for high turnover (in average 20-fold higher than 
indicated by 14C birth dating). IdU is a radiosensitizer, sometimes used in cancer 
treatments, and labels cells during DNA synthesis. Therefore if many cardiomyocytes 
are positive for IdU soon after the IdU treatment it may indicate high turnover. 
However, high turnover will also dilute the IdU-label with time, so the time between 
treatment and death is important when drawing conclusions on the turnover level. By 
taking this into account we showed that the number of IdU positive cardiomyocytes 
and the turnover reported in the study were not compatible with each other. The 
inconsistency could probably be explained by DNA repair during the cancer 
treatment.       
In Paper II we extended the analysis to include several aspects of cardiac 
renewal to provide a comprehensive view of the regenerative capacity of the healthy 
heart. We found that the total number of cardiomyocytes stays constant over lifetime, 
while endothelial and mesenchymal cell numbers increase during the first decades in 
life. Cardiomyocytes in different regions of the heart (left and right ventricles, apex, 
base, endocardium, and epicardium) as well as different subpopulations (diploid, 
tetraploid, and octaploid) turn over to the same degree, which is consistent with the 
dynamics found in Paper IV. An independent study that also looked at cardiomyocyte 
numbers in growing human hearts, using design-based stereology, a 3.4-fold increase 
during the first 20 years in life was found, in contrast to us (Mollova et al., 2013). In 
stereology, cell nuclei are used as landmarks for cells and without a marker for 
cardiomyocyte nuclei it is difficult to appreciate which nuclei belong to which cell. 
This in combination with the fact that cardiomyocytes are small in young ages, and 
that the nuclei are closely positioned, could possibly explain the differences between 
our studies.   
In Paper I we investigated cardiomyocyte turnover in human heart disease 
(ischemic heart disease and dilated cardiomyopathy). We found that cardiomyocytes 
in diseased hearts have increased DNA synthesis and that this is mainly due to 
polyploidization. Preliminary results on turnover indicate that it increases to 2.7% per 
year during the disease, but that individual turnover rates probably deviate from this. 
Data on diploid and polyploid cardiomyocytes suggest heterogeneity in the 
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population, such that postnatally born cardiomyocytes are more likely to ploidize and 
die than the original neonatal population. However, it will be important to analyze 
these findings further for statistical significance. The idea of cardiomyocyte 
heterogeneity is exciting as it could bring us closer to discerning the phenotype and 
mechanisms of cardiomyocytes that can regenerate. Interestingly, it has recently been 
suggested that in mice a subset of cardiomyocytes are hypoxic and that these cells 
have higher proliferative capacity (Kimura et al., 2015).      
The discrepancies between our findings and the opposing results, mainly 
reported by Prof. Anversa and colleagues, are most likely due to the different 
experimental methods used and their approach to data interpretation. Not all scientific 
findings will withstand the test of time and it is inevitable that some turn out to be 
pieces of the puzzle that did not fit. In this respect we can note that during the last 
couple of years evidence is accumulating that supports our view on the regenerative 
capacity of the heart (van Berlo and Molkentin, 2014).       
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CONCLUDING REMARKS  
 
Our investigation into the regenerative capacity of the human heart has provided 
promising evidence that cardiomyocytes have the capacity to renew in all stages of 
postnatal and adult life, and that heart disease has the potential to increase it. The non-
myocyte cell populations are more dynamic, both with respect to changes in cell 
number and baseline renewal. The findings presented in this thesis suggest that it is 
both reasonable and realistic to work towards improving regenerative heart therapies 
focusing on enhancing the endogenous regeneration. The results presented here would 
not have been possible without the consequences of the above ground detonations of 
nuclear weapons during the Cold War; it has truly given us a unique opportunity to 
study human tissues retrospectively. The multidisciplinary aspect of the 14C birth 
dating project is also expected to result in improvements in fields other than 
regenerative heart medicine. It is now already possible to measure smaller carbon 
samples using accelerator mass spectrometry, which benefit therapeutic microdosing 
experiments with 14C labeled carbon compounds. Moreover, our developments and 
extensions of the mathematical model for cell turnover could be useful for describing 
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